Allyx Therapeutics

Executive Summary

Allyx Therapeutics is a clinical-stage biotech company pioneering small molecule therapeutics that target synaptic dysfunction to reverse neurodegeneration. Founded by Yale scientists and industry veterans, its lead candidate, ALX-001, is an oral mGluR5 antagonist designed to normalize aberrant synaptic signaling implicated in Alzheimer's and Parkinson's diseases. The approach is based on decades of research linking mGluR5 to toxic protein aggregation and synaptic loss. ALX-001 has shown promise in preclinical models, and the company is advancing it through clinical development. Allyx's platform has the potential to address multiple neurodegenerative conditions beyond Alzheimer's, including Parkinson's disease, for which programs are expanding.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data readout for ALX-001 in Alzheimer's disease40% success
• Q2 2027Initiation of Phase 1 trial for ALX-001 in Parkinson's disease60% success
• H2 2026Series B financing or strategic partnership50% success